Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00898742 · ClinicalTrials.gov registry record
Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer
A clinical trial, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- 58
- Enrollment target
NCT00898742 is a clinical trial that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 58 participants.
The verdict
NCT00898742 was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- 58 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how will patients respond to treatment. PURPOSE: This research study is looking at gene and protein expression patterns in predicting response to cetuximab in patients with recurrent and/or metastatic head and neck cancer.
Interventions
- OTHER mass spectrometry
- GENETIC reverse transcriptase-polymerase chain reaction
- GENETIC DNA and tissue microarray analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2007-04 |
| Est. Completion | 2010-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00898742
The ClinicalTrials.gov registry entry for NCT00898742 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which mass spectrometry is the first listed.
NCT00898742 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00898742 about?
NCT00898742 is a clinical study titled "Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer". RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how will patients respond to treatment. PURPOSE: This research study is loo...
What is the current status of trial NCT00898742?
This trial is currently terminated. The enrollment target is 58 participants. The study started on 2007-04. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00898742?
The interventions under investigation include: mass spectrometry (OTHER), reverse transcriptase-polymerase chain reaction (GENETIC), DNA and tissue microarray analysis (GENETIC).
Who is sponsoring clinical trial NCT00898742?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.